RedHill Biopharma (RDHL) Equity Ratio (2016 - 2025)
Historic Equity Ratio for RedHill Biopharma (RDHL) over the last 11 years, with Q4 2024 value amounting to 0.26.
- RedHill Biopharma's Equity Ratio fell 38911.41% to 0.26 in Q4 2024 from the same period last year, while for Dec 2024 it was 0.26, marking a year-over-year decrease of 38911.41%. This contributed to the annual value of 0.26 for FY2024, which is 38911.41% down from last year.
- Latest data reveals that RedHill Biopharma reported Equity Ratio of 0.26 as of Q4 2024, which was down 38911.41% from 0.09 recorded in Q4 2023.
- Over the past 5 years, RedHill Biopharma's Equity Ratio peaked at 0.09 during Q4 2023, and registered a low of 0.3 during Q4 2022.
- Over the past 5 years, RedHill Biopharma's median Equity Ratio value was 0.05 (recorded in 2021), while the average stood at 0.07.
- As far as peak fluctuations go, RedHill Biopharma's Equity Ratio tumbled by 72196.3% in 2022, and later skyrocketed by 12946.75% in 2023.
- Quarter analysis of 5 years shows RedHill Biopharma's Equity Ratio stood at 0.08 in 2020, then tumbled by 36.32% to 0.05 in 2021, then crashed by 721.96% to 0.3 in 2022, then skyrocketed by 129.47% to 0.09 in 2023, then crashed by 389.11% to 0.26 in 2024.
- Its Equity Ratio stands at 0.26 for Q4 2024, versus 0.09 for Q4 2023 and 0.3 for Q4 2022.